Structure-based in silico investigation of antagonists of human ribonucleotide reductase from Annona muricata
Human ribonucleotide reductase (HRR) also known as ribonuceotide diphosphate reductase catalyzes the conversion of ribonucleotide to deoxyribonuceotides which is the rate limiting step in the synthesis of DNA, establishing the enzyme as a vital therapeutic target in discovery of cancer drugs. Hence,...
Autores principales: | Damilola A. Omoboyowa, Damilola S. Bodun, Jamiyu A. Saliu |
---|---|
Formato: | Artículo |
Lenguaje: | English |
Publicado: |
Elsevier
2023-01-01
|
Colección: | Informatics in Medicine Unlocked |
Materias: | |
Acceso en línea: | http://www.sciencedirect.com/science/article/pii/S2352914823000679 |
Ejemplares similares
-
Advances of Ribonucleotide Reductase Inhibitors on Cancer
por: WANG An'ge, et al.
Publicado: (2019-08-01) -
Inhibitors of the Cancer Target Ribonucleotide Reductase, Past and Present
por: Sarah E. Huff, et al.
Publicado: (2022-06-01) -
Structure-guided design of anti-cancer ribonucleotide reductase inhibitors
por: Tessianna A. Misko, et al.
Publicado: (2019-01-01) -
Design and synthesis of potential ribonucleotide reductase enzyme (RNR) inhibitors as antileukemic and/or antiviral 2′-deoxymethylene nucleosides
por: Khairia M. Youssef, et al.
Publicado: (2015-12-01) -
Sorafenib Inhibits Ribonucleotide Reductase Regulatory Subunit M2 (RRM2) in Hepatocellular Carcinoma Cells
por: Pei-Ming Yang, et al.
Publicado: (2020-01-01)